For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Lilly Icos LLC

USPTO Granted Patents = 25

% Expired Patents = 76.0

CIPO Patents = 1

Trademarks = 2

Forward Citations = 187

Loading Chart...

Loading Chart...

31 inventors (with patents filed for the assignee):

Mark W Orme (18 out of 68 patents)

Jason Scott Sawyer (17 out of 72 patents)

Lisa M Schultze (10 out of 10 patents)

4. Alain Claude-Marie Daugan (7 out of 26 patents)

5. Neil R Anderson (3 out of 7 patents)

6. Raymond F Brown (3 out of 3 patents)

7. Agnes Bombrun (3 out of 3 patents)

8. William Ernest Pullman (3 out of 3 patents)

9. Kenneth M Ferguson (2 out of 5 patents)

10. Romain Luc Marie Gosmini (2 out of 10 patents)

11. Martha A Kral (2 out of 2 patents)

12. Françoise Jeanne Gellibert (2 out of 3 patents)

13. John Steven Whitaker (2 out of 2 patents)

14. Romain Luc Gosmini (2 out of 3 patents)

15. Nerina Dodic (1 out of 6 patents)

Core Competencies:

PDE5 Inhibitors

Carboline Derivatives

Pharmaceutical Compositions

Neuropathies

Sexual Dysfunction

Cardiovascular Disorders

Heterocyclic Derivatives

Indole Derivatives

Pyrazino Compounds

Beta-Carboline

GMP-Specific Inhibitors

Condensed Derivatives

25 patents: Sort by Forward Citations

1. 7550479 - Modified Pictet-Spengler reaction and products prepared therefrom (2009-06-23),

2. 7338955 - Medicament for treatment of neuropathies (2008-03-04),

3. 7182958 - β-carboline pharmaceutical compositions (2007-02-27),

4. 7122554 - Carboline derivatives (2006-10-17),

5. 7115621 - Chemical compounds (2006-10-03),

6. 7105506 - Tetracyclic compounds as PDE5-inhibitors (2006-09-12),

7. 7098209 - Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives (2006-08-29),

8. 7034027 - Fused heterocyclic derivatives as phosphodiesterase inhibitors (2006-04-25),

9. 7022856 - Carboline derivatives (2006-04-04),

10. 6992192 - Carboline derivatives as PDE5 inhibitors (2006-01-31),

11. 6984641 - Carboline derivatives as PDE5 inhibitors (2006-01-10),

12. 6962918 - Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction (2005-11-08),

13. 6960587 - Condensed pyrazindione derivatives as PDE inhibitors (2005-11-01),

14. 6943166 - Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction (2005-09-13),

15. 6911542 - Pyrazino[1',2′:1,6]pyrido[3,4b]indole derivatives (2005-06-28),

Company Overview

Lilly Icos LLC, based in Wilmington, DE, is a biopharmaceutical company specializing in the development and commercialization of innovative therapies. The organization focuses on advancing treatments in various therapeutic areas, including endocrinology and oncology, leveraging cutting-edge research and technology. With a commitment to improving patient outcomes, Lilly Icos collaborates with healthcare professionals and researchers to address unmet medical needs and enhance the quality of life for patients globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

25 Patents

#187 in Wilmington, DE

#226 in Delaware

#13,370 in US

#25,730 in the World

Wilmington, DE, United States of America

Lilly Icos LLC

Forward Citations = 187

31 inventors:

Mark W Orme (18 out of 68 patents)

Jason Scott Sawyer (17 out of 72 patents)

Lisa M Schultze (10 out of 10 patents)

4. Alain Claude-Marie Daugan (7 out of 26 patents)

5. Neil R Anderson (3 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lilly Icos LLC. Retrieved from https://idiyas.com/company/lilly-icos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…